Vascular anomalies (VAs) are a diverse group of vascular tumors and vascular malformations (VMs). VMs are characterized by abnormal vessel development, overgrowth, and dysfunction. Coagulopathy, edema, and effusions can cause severe morbidity and mortality in children and adults with these diseases. Germline or somatic mutations in the RAS/RAF/MAPK pathway have been identified in multiple types of VAs. RAS genes ( KRAS , NRAS , and HRAS ) are small GTPase proteins that play an important role in normal development and cell function. In healthy cells, RAS proteins cycle between GDP (inactive) and GTP (active) states that regulate important functions such as proliferation, migration, and survival. “Hot spot” mutations in codons 12, 13, or 61 of RAS genes are found in multiple tumor types and VAs. RAS mutations often cause excessive MAP kinase signaling, driving unchecked cell proliferation. In this review, we discuss the different RAS pathway mutations discovered in VAs and the role that these may play using insights from cell and animal models. Current therapies targeting RAS pathways are presented. In the future, a better understanding of the role of RAS pathway mutations may advance therapeutic strategies for people with VAs.
RAS mutations occur in patients with several types of vascular anomalies, but effective treatments remain limited. To address this need, we evaluated the RAS (ON) multi‐selective inhibitor RMC‐7977 in human endothelial cells (ECs) expressing the NRAS Q61R mutation found in kaposiform lymphangiomatosis (KLA). RMC‐7977 was evaluated using in vitro and in vivo models. Doxycycline‐inducible NRAS WT and NRAS Q61R human ECs were treated with RMC‐7977 (3.12–100 nM) or vehicle. We assessed signalling pathways, proliferation, migration, morphology, and angiopoietin‐2 (ANG‐2) production. NRAS Q61R ECs in a 3D angiogenesis assay were also treated with RMC‐7977. For in vivo studies, NRAS Q61R ECs were injected into flanks of nude mice on a doxycycline diet to generate xenografts. Mice received oral RMC‐7977 or vehicle, and xenografts were collected after 11 days. RMC‐7977 inhibited NRAS Q61R ‐induced ERK phosphorylation and reduced proliferation, migration, spindle‐like morphology, and ANG‐2 production in a dose‐dependent manner. RMC‐7977 reduced vascular area in the angiogenesis assay. In vivo, RMC‐7977 reduced xenograft weight, vascular area, and p‐ERK staining. Overall, RMC‐7977 suppressed NRAS Q61R ‐mediated signalling, aberrant EC behaviour, and ANG‐2 production in vitro and reduced vascular overgrowth in angiogenesis assays and mouse xenografts. Therefore, RMC‐7977 may be a promising therapeutic candidate for RAS‐driven vascular anomalies, including KLA.
13 July 2026 in Blood Vessels, Thrombosis & Hemostasis